Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators.
Wang H, van de Bovenkamp FS, Dijkstra DJ, Abendstein L, Borggreven NV, Pool J, Zuijderduijn R, Gstöttner C, Gelderman KA, Damelang T, Vidarsson G, Blom AM, Domínguez-Vega E, Parren PWHI, Sharp TH, Trouw LA. Wang H, et al. Among authors: parren pwhi. Front Immunol. 2024 May 16;15:1288597. doi: 10.3389/fimmu.2024.1288597. eCollection 2024. Front Immunol. 2024. PMID: 38817607 Free PMC article.
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Lameris R, Ruben JM, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp FS, de Weerdt I, Kater AP, Zweegman S, Horbach S, Riedl T, Winograd B, Roovers RC, Adang AEP, de Gruijl TD, Parren PWHI, van der Vliet HJ. Lameris R, et al. Among authors: parren pwhi. Cell Rep Med. 2023 Mar 21;4(3):100961. doi: 10.1016/j.xcrm.2023.100961. Epub 2023 Mar 2. Cell Rep Med. 2023. PMID: 36868236 Free PMC article.
Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells.
van der Wulp W, Gram AM, Bleijlevens B, Hagedoorn RS, Araman C, Kim RQ, Drijfhout JW, Parren PWHI, Hibbert RG, Hoeben RC, van Kasteren SI, Schuurman J, Ressing ME, Heemskerk MHM. van der Wulp W, et al. Among authors: parren pwhi. Front Immunol. 2023 May 16;14:1183914. doi: 10.3389/fimmu.2023.1183914. eCollection 2023. Front Immunol. 2023. PMID: 37261346 Free PMC article.
Antibody avidity meets multiple myeloma.
Ruuls SR, Parren PWHI. Ruuls SR, et al. Among authors: parren pwhi. Nat Cancer. 2024 Oct;5(10):1452-1454. doi: 10.1038/s43018-024-00805-1. Nat Cancer. 2024. PMID: 39261677 No abstract available.
Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation.
Dijkstra DJ, van de Bovenkamp FS, Abendstein L, Zuijderduijn R, Pool J, Kramer CSM, Slot LM, Drijfhout JW, de Vor L, Gelderman KA, Rooijakkers SHM, Zaldumbide A, Vidarsson G, Sharp TH, Parren PWHI, Trouw LA. Dijkstra DJ, et al. Among authors: parren pwhi. Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2310666120. doi: 10.1073/pnas.2310666120. Epub 2023 Dec 4. Proc Natl Acad Sci U S A. 2023. PMID: 38048459 Free PMC article.
Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells.
van der Wulp W, Remst DFG, Kester MGD, Hagedoorn RS, Parren PWHI, van Kasteren SI, Schuurman J, Hoeben RC, Ressing ME, Bleijlevens B, Heemskerk MHM. van der Wulp W, et al. Among authors: parren pwhi. Cancer Gene Ther. 2024 Jan;31(1):58-68. doi: 10.1038/s41417-023-00681-4. Epub 2023 Nov 9. Cancer Gene Ther. 2024. PMID: 37945970 Free PMC article.
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA, Toffoli EC, Veth M, Iglesias-Guimarais V, Slot MC, Amsen D, van de Ven R, Derks S, Fransen MF, Tuynman JB, Riedl T, Roovers RC, Adang AEP, Ruben JM, Parren PWHI, de Gruijl TD, van der Vliet HJ. King LA, et al. Among authors: parren pwhi. Cancer Immunol Res. 2023 Sep 1;11(9):1237-1252. doi: 10.1158/2326-6066.CIR-23-0189. Cancer Immunol Res. 2023. PMID: 37368791
Avidity in antibody effector functions and biotherapeutic drug design.
Oostindie SC, Lazar GA, Schuurman J, Parren PWHI. Oostindie SC, et al. Among authors: parren pwhi. Nat Rev Drug Discov. 2022 Oct;21(10):715-735. doi: 10.1038/s41573-022-00501-8. Epub 2022 Jul 5. Nat Rev Drug Discov. 2022. PMID: 35790857 Free PMC article. Review.
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
Saura-Esteller J, de Jong M, King LA, Ensing E, Winograd B, de Gruijl TD, Parren PWHI, van der Vliet HJ. Saura-Esteller J, et al. Among authors: parren pwhi. Front Immunol. 2022 Jun 16;13:915837. doi: 10.3389/fimmu.2022.915837. eCollection 2022. Front Immunol. 2022. PMID: 35784326 Free PMC article. Review.
160 results